Myeloperoxidase-and proteinase 3-anti-neutrophil cytoplasmic antibodies (ANCAs) are often negative in cases in which systemic vasculitis is highly suspected. We herein present a case of bactericidal/permeability increasing protein (BPI)-ANCA-positive systemic vasculitis. This case highlights the possible role of BPI-ANCA in the pathogenesis of systemic vasculitis as well as the possible use of BPI as a diagnostic tool. The accumulation of further case-based reports is expected to shed some light on the pathogesis of systemic vasculitis.
Introduction
Anti-neutrophil cytoplasmic antibodies (ANCAs) are autoantibodies produced in response to neutrophil cytoplasmic enzymes, and evaluating the levels of ANCAs is useful for making a diagnosis of systemic vasculitis such as granulomatosis with polyangiitis (Wegener's) (GPA) or microscopic polyarteritis (MPA) (1, 2) . ANCAs have been analyzed using immunofluorescence assay (IFA) and are classified according to dyeing patterns into cytoplasmic-ANCA (c-ANCA) or perinuclear-ANCA (p-ANCA). Enzyme-linked immunosorbent assay (ELISA), which is currently the most popular assay, can detect myeloperoxidase (MPO)-and proteinase 3 (PR3)-ANCAs.
The majority of p-ANCAs and c-ANCAs have been proven to be equivalent to MPO-and PR3-ANCAs, respectively. Patients with MPA and Churg-Strauss syndrome are positive for p-ANCA, and those with GPA are positive for c-ANCA (3) (4) (5) . In patients with active systemic GPA, MPA or Churg-Strauss syndrome, ANCAs are reported to be positive in over 80%, 70% or 50% of cases, respectively (5) . Moreover, as ELISA provides a good detection rate and useful results, we analyzed the levels of MPO-and PR3-ANCAs to make a diagnosis of systemic vasculitis in the current clinical setting.
In this way, analyzing the levels of MPO-and PR3-ANCAs is very useful for making a diagnosis of systemic vasculitis. However, some patients are negative for both MPO-and PR3-ANCAs while other clinical findings strongly suggest the presence of systemic vasculitis, which makes diagnosing systemic vasculitis difficult.
We herein present a case of systemic vasculitis in which MPO-and PR3-ANCAs were negative while bactericidal/ permeability increasing protein (BPI)-ANCA was positive. 
Case Report
A 71-year-old woman visited our hospital with bloody sputum, coughing and general malaise. She had a history of diabetes mellitus, hyperlipidemia and chronic bronchitis, and hematuria and urinary protein had been previously detected. The patient's occupational history included work in agriculture, the civil engineering industry and the agricultural industry with mild dust inhalation. She had a family history of cancer: her grandfather, parents and an older brother had developed stomach cancer, while a younger brother had developed lung cancer and diabetes. The patient did not smoke or drink alcohol. Over a couple of months, she had lost two kilograms.
She complained of coughing, sputum production and dyspnea persisting over the last few years, and her symptoms gradually progressed over a few months. Although macroscopic hematuria was noted in December 2008, it disappeared within a few days. The patient consulted a personal doctor in January 2009, at which time chest radiography showed diffuse consolidation in the bilateral lung fields. She was thereafter referred to our hospital and admitted for further examination.
The patient's physical findings on admission were as follows: height, 140 cm; body weight, 57 kg; body temperature, 36.6 ; blood pressure, 188/105 mmHg; pulse rate, 125 beats/min; SpO2, 91% (under inhalation of 3 L/min oxygen via nasal cannula). Her consciousness was clear. Fine crackles were present in both lung fields and coarse crackles were present in the right lung field. The patient's abdomen was flat and soft with no tenderness. There was a small amount of edema in the extremities.
The results of laboratory examinations were as follows: urine sugar, urinary protein, and occult hematuria tests were positive; white cell count, 13,300/μL; red cell count, 300× 10 4 /μL; hemoglobin, 9.1 g/dL; serum lactate dehydrogenase, 310 IU/L; serum blood urea nitrogen, 68 mg/dL; serum creatinine, 5.11 mg/dL; serum potassium, 5.9 mEq/L; sialylated carbohydrate antigen KL-6, 923 U/mL; surfactant protein D, 344.6 ng/mL; surfactant protein A, 94.0 ng/mL. Autoimmune antibodies, such as MPO-ANCA, PR3-ANCA and anti-glomerular basement membrane (GBM) antibodies were all negative, except for anti-DNA antibodies ( Table 1) . Sputum cultures were negative. Chest roentgenogram showed consolidation in the bilateral lung fields, and chest computed tomography (CT) revealed consolidation in the right middle and lower lobes of the lungs with reticular and cystic shadows in the bilateral dorsal lower lung fields and a small amount of bilateral pleural effusion ( Fig. 1 ).
Since the level of anti-DNA antibodies was elevated, the patient was suspected as having a form of systemic vasculitis such as systemic lupus erythematosus (SLE). However, she was not given a diagnosis of systemic vasculitis due to the negative results of MPO-, PR3-ANCA and anti-GBM antibodies. As bronchoscopy could not be performed due to the patient's severe respiratory condition, we completed a renal biopsy to determine the pathological diagnosis of the kidney disease. The pathological findings of the renal biopsy revealed crescent formations in almost all of the glomeruli, leading to a diagnosis of crescentic glomerulonephritis (Fig. 2) . Because the CT findings suggested the presence of interstitial pneumonia, we speculated that the patient also had systemic vasculitis. To make a definitive diagnosis, we next examined ANCAs using IFA. The IFA assay disclosed positive findings of c-ANCA and negative findings of p-ANCA in spite of the negative results of MPO-and PR3-ANCAs found on ELISA. These results suggested the involvement of other ANCAs in the patient's clinical condition. Therefore, we conducted screening of ANCAs using an ANCA panel kit Wieslab (Euro-Diagnostica, Sweden) and thus found BPI-ANCA to be positive ( Table 2 ). Because the patient had no symptoms suggesting SLE, she was therefore diagnosed to have BPI-ANCA-positive microscopic polyarteritis associated with interstitial pneumonia and crescent glomerulonephritis. Steroid pulse therapy (methylprednisolone 1 g/day, three days) followed by oral prednisolone (60 mg/day) was started in addition to cyclophosphamide pulse therapy (500 mg/ month). After the initiation of treatment, a slight improvement in the renal function and a significant improvement in the chest radiograph findings were noted (Fig. 3) . The hypoxemia also improved, and the patient was considered to have achieved clinical remission. The value of BPI-ANCA reanalyzed five months after the initiation of immunosuppressive therapy was within the normal range (1.3 index).
Discussion
ANCAs are serological biomarkers in patients with systemic vasculitis, and certain types of vasculitis have been shown to be correlated with the IFA patterns of c-ANCA and p-ANCA. However, because the majority of c-ANCAs and p-ANCAs are recognized to be equivalent to PR3-ANCAs and MPO-ANCAs, respectively, evaluating the levels of ANCAs using ELISA is currently more commonly used than IFA (2, (4) (5) (6) . Human neutrophils contain at least three types of granules, including azurophilic, secondary and tertiary granules, each of which contains a variety of proteins. Therefore, antibodies against many constituent proteins can be produced. In fact, there are other types of ANCAs that are neither PR3-nor MPO-ANCAs. Approxi- CT obtained at 22 days (B, C) showed that the consolidation had almost disappeared; however, the reticular and cystic shadows remained in the bilateral dorsal lower lung fields.
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mately 80% of patients whose serum is positive for p-ANCA or c-ANCA, but negative for both PR3-and MPO-ANCAs, have been reported to be positive for other AN-CAs, such as anti-BPI, cathepsin G, lactoferrin, elastase, azurocidin and lysozyme antibodies (7, 8) . These are observed less frequently than MPO-and PR3-ANCAs and are known to be minor ANCAs (x-ANCA). BPI-ANCA was reported by Zhao et al. to be a x-ANCA in 1995 (9) . BPI is a protein that is abundantly found in azurophilic granules of neutrophils and plays an important role in antibacterial defense against Gram-negative bacteria. Endotoxin and bacterial outer membrane proteins have a strong affinity for BPI and form complexes with BPI. These complexes are processed by antigen presenting cells leading to the generation of BPI-ANCA (10). BPI-ANCA has been documented in a variety of pulmonary diseases, including cystic fibrosis ( CF ) (11), diffuse panbronchiolitis (DPB) (12) , bronchiectasis (13) and rheumatoid arthritis with bronchial involvement (14) . In particular, 91% of CF patients are reported to be positive for BPI-ANCA (11) .
Whether BPI-ANCA is pathogenic or merely a serological marker of disease remains uncertain. Although detecting BPI-ANCA may reflect a possible secondary reaction to chronic inflammation, the pathogenic role of BPI-ANCA in the development of CF has been indicated (11, 15) . Patients with defects in transporter associated with antigen presentation (TAP) are known to suffer from recurrent bacterial infections starting in early childhood. Schultz et al. reported that BPI-ANCA is frequently positive in TAP-deficient pa-tients and described the possible role of BPI-ANCA in susceptibility to Gram-negative bacterial infections in such patients. In fact, they demonstrated that BPI-ANCA-positive sera obtained from TAP-deficient patients inhibit the antimicrobial function of BPI in vitro (16) . In this regard, there is growing evidence showing that BPI-ANCA plays a pivotal role in the pathogenesis of bacterial infections. In our case, there was no evidence of bacterial infection; however, the clinical findings suggested the possible role of BPI-ANCA in systemic vasculitis.
Zhao et al. reported that 45 of 100 double-negative samples evaluated with ELISA were positive for anti-BPI (9) , thus suggesting that the presence of BPI-ANCA may not be rare. Talor et al. reported that three patients whose serum was found to be positive for MPO and PR3 on IFA but negative on ELISA were given a diagnosis of MPA. One of the patients was positive for anti-BPI antibodies and another was positive for anti-lactoferrin antibodies (8) . In Japan, there have only been three reports written in English describing patients with BPI-ANCA to date (12) (13) (14) . To the best of our knowledge, this is the first report describing BPI-ANCA-related systemic vasculitis with interstitial pneumonia.
We have often experienced patients that were clinically highly suspected of having systemic vasculitis who were found to be negative for PR3-and MPO-ANCAs. In such cases, one x-ANCA may be present. Although measuring the levels of x-ANCA is not allowed under insurancecovered health care in Japan, analyzing x-ANCA may be useful in the diagnostic process of investigating systemic vasculitis. Normative treatment for vasculitis with ANCA (17) (18) (19) was initiated in our case, and a state of remission was achieved with steroid and cyclophosphamide therapies. However, accumulating case-based reports is necessary to determine the established treatment.
We herein reported a case of systemic vasculitis in a patient whose serum was negative for MPO-and PR3-ANCAs but positive for BPI-ANCA on ANCA screening. The present case, which is the first report in Japan of pulmonary manifestations in a patient with BPI-ANCA-positive systemic vasculitis, suggests that 1) ANCA screening is useful for diagnosing systemic vasculitis when the patient's serum is negative for MPO-and PR3-ANCAs and 2) the possible role of BPI-ANCA in the pathogenesis of systemic vasculitis.
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